Abstract
Pancreatic cancer has the worst prognosis among all cancers1. Cancer screening programs based on the analysis of body fluids can improve the survival time of patients, who are often diagnosed too late at an incurable stage2. Several studies have reported the dysregulation of lipid metabolism in tumor cells and tissues3, suggesting that the changes of blood lipidome may accompany tumor growth and progression. Analytical methods based on mass spectrometry (MS) using either direct infusion or chromatographic separation4 are convenient for high-throughput lipidomic profiling. Here we show that the comprehensive quantitation of a wide range of serum lipids reveals statistically significant differences between pancreatic cancer patients and healthy controls visualized by multivariate data analysis. Initial results for 364 human serum samples in the discovery phase were subsequently verified in the qualification phase on 554 samples measured by three independent laboratories, and finally on 830 samples from four blood collection sites in the verification phase. Concentrations suggestive of dysregulation of some very long chain sphingomyelins (SM 42:1, SM 41:1, SM 39:1, and SM 40:1), ceramides (Cer 41:1, and Cer 42:1), and (lyso)phosphatidylcholines (LPC 18:2) were recorded. Some lipid species indicated a potential as biomarkers of survival. The sensitivity and specificity to diagnose pancreatic cancer is over 90%, which outperforms CA 19-9, especially in early stage, and is comparable to established imaging diagnostic methods. The accuracy of lipidomic approach is not influenced by the cancer stage, analytical method, or blood collection site.
Competing Interest Statement
M.H., E.C., R.J., and D.W. are listed as inventors on patent EP 3514545 related to this work.
Funding Statement
The project was funded by the project 18-12204S (the Czech Science Foundation). L.K. acknowledges the support of institutional program of the Charles University in Prague (UNCE 204064). R.H. acknowledges the support of MEYS BBMRI CZ LM2018125 (the Ministry of Education, Youth and Sports of the Czech Republic) and MH CZ DRO (MMCI, 00209805, the Ministry of Health of the Czech Republic) projects.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committe / Masaryk Memorial Cancer Institute 2019/1821/MOU, MOU 274585
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data necessary to support the conclusions are available in the manuscript or supplementary information. Raw data, instructions for the software handling and the software are deposited at figshare.com.
https://figshare.com/s/5ddbcbf1be4a1aec966f
https://figshare.com/s/b28049603a4f361c818b
https://figshare.com/s/40f1450376cdc8d69e9a
https://figshare.com/s/cb071be45cd91a7c90e2
https://figshare.com/s/1fd10f273b049b93fa24
